| Endometriosis
Zoladex vs Myfembree
Side-by-side clinical, coverage, and cost comparison for endometriosis.Deep comparison between: Zoladex vs Myfembree with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMyfembree has a higher rate of injection site reactions vs Zoladex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Myfembree but not Zoladex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoladex
Myfembree
At A Glance
SC injection
Every 28 days
GnRH agonist
Oral
Daily
GnRH receptor antagonist
Indications
- Prostate carcinoma
- Endometriosis
- Abnormal uterine bleeding
- Breast Carcinoma
- Uterine Fibroids
- Menorrhagia
- Endometriosis
Dosing
Prostate carcinoma (Stage B2-C) 3.6 mg SC every 28 days starting 8 weeks before radiotherapy, in combination with flutamide, continued during radiation therapy; alternatively, a 10.8 mg depot may follow the initial 3.6 mg depot.
Prostate carcinoma (advanced) 3.6 mg SC every 28 days; intended for long-term administration.
Endometriosis 3.6 mg SC every 28 days for 6 months.
Abnormal uterine bleeding One or two 3.6 mg SC depots given 4 weeks apart; surgery performed at 4 weeks after one depot, or within 2-4 weeks after the second depot.
Breast Carcinoma 3.6 mg SC every 28 days; intended for long-term administration.
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Contraindications
- Known hypersensitivity to GnRH, GnRH agonist analogues, or any component of ZOLADEX
- Pregnancy (except when used for palliative treatment of advanced breast cancer)
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
Adverse Reactions
Most common (>10%) in men Hot flashes, sexual dysfunction, decreased erections, lower urinary tract symptoms
Most common (>20%) in women Hot flushes, headache, sweating, acne, emotional lability, depression, decreased libido, vaginitis, breast atrophy, seborrhea, peripheral edema
Serious Tumor flare, ureteral obstruction, spinal cord compression, pituitary apoplexy
Postmarketing Osteoporosis, bone fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, ovarian cyst, pituitary adenoma, SJS/TEN, DRESS, AGEP, erythema multiforme, psychotic disorders, suicidal ideation, convulsions
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Pharmacology
ZOLADEX is a synthetic decapeptide analogue of GnRH that inhibits pituitary gonadotropin secretion; chronic administration suppresses serum testosterone in males to castrate levels and reduces serum estradiol in females to postmenopausal levels, leading to regression of hormone-sensitive tumors and accessory sex organ regression.
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoladex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
UnitedHealthcare
Zoladex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Zoladex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zoladex.
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoladexView full Zoladex profile
MyfembreeView full Myfembree profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.